Phase II Evaluation of Safety, Tolerability, and Efficacy of BI 730357 in Patients With Moderate-to-severe Plaque Psoriasis
收藏DataCite Commons2025-06-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011150/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective is based on Week 12 co-primary endpoints of PASI (Psoriasis Area and Severity Index) 75 and sPGA (Static Physician's Global Assessment) 0/1, and overall safety Secondary objectives of Part 1 are to evaluate the efficacy and safety of BI 730357 through 24 weeks of treatment
提供机构：
Vivli
创建时间：
2025-03-04
